Fri, January 24, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Wamsi Mohan Maintained (AAPL) at Buy with Decreased Target to $253 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Paul Lejuez Reinstated (ACI) to Buy and Held Target at $26 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Brett Fishbin Maintained (ALC) at Overweight with Decreased Target to $105 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David Saxon Maintained (ALC) at Buy with Decreased Target to $106 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Gregory Renza Reiterated (AMGN) at Outperform and Held Target at $324 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Richard Hightower Maintained (AMH) at Equal with Decreased Target to $37 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David George Maintained (ASB) at Neutral with Decreased Target to $26 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Karl Shepard Maintained (ASB) at Sector with Increased Target to $27 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Adam Kramer Downgraded (AVB) to Equal and Decreased Target to $223 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Richard Hightower Maintained (AVB) at Equal with Decreased Target to $230 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Jason Gursky Maintained (BA) at Buy with Decreased Target to $207 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Jared Shaw Maintained (BANC) at Overweight with Decreased Target to $19 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
David Williams Reiterated (BDC) at Buy and Held Target at $130 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Fawne Jiang Reiterated (BIDU) at Buy and Held Target at $130 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Joseph Greff Maintained (BYD) at Neutral with Increased Target to $80 on, Jan 24th, 2025
[ Fri, Jan 24th 2025 ]: WOPRAI
Matthew Akers Maintained (CACI) at Overweight with Increased Target to $536 on, Jan 24th, 2025
Thu, January 23, 2025
[ Thu, Jan 23rd 2025 ]: MSN
Avidity Biosciences CFO sells $93,985 in stock
[ Thu, Jan 23rd 2025 ]: MSN
2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025
[ Thu, Jan 23rd 2025 ]: MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook
[ Thu, Jan 23rd 2025 ]: MSN
Diamondback Energy's SWOT analysis: stock poised for growth amid merger synergies
[ Thu, Jan 23rd 2025 ]: Forbes
S&P 500 Index Funds: Risks You Must Know Before You Invest
[ Thu, Jan 23rd 2025 ]: MSN
Are famous short-sellers going extinct? The exit .. nd Andrew Left shows the risky trade is shrinking
[ Thu, Jan 23rd 2025 ]: MSN
Is AbbVie Inc. (ABBV) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: MSN
Is Intel Corporation (INTC) One of the Best Socia .. sponsible Stocks to Buy According to Hedge Funds?
[ Thu, Jan 23rd 2025 ]: Forbes
Is Quantum Computing Investable As The Next AI
[ Thu, Jan 23rd 2025 ]: MSN
Is Johnson & Johnson (JNJ) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: MSN
BlackRock CEO Fink advocates for tokenization of stocks and bonds
[ Thu, Jan 23rd 2025 ]: MSN
Is PepsiCo, Inc. (PEP) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: AOL
Warren Buffett: 5 Stocks He's Dead Serious About In 2025
[ Thu, Jan 23rd 2025 ]: MSN
Is Medtronic plc (MDT) the Best Halal Dividend Stock to Invest In Now?
[ Thu, Jan 23rd 2025 ]: Forbes
What Are The Risks Of S&P 500 Index Funds?
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of IIIV at $2 .. 7, after crossing above the $24.468 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of EYPT at $8.86, after crossing above the $8.78 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of FMAO at $2 .. 7, after crossing above the $26.264 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of PLAY at $2 .. 4, after crossing above the $27.587 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of CHGCF at $ .. 2, after crossing above the $44.189 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of ACIC at $1 .. 2, after crossing above the $12.149 Trigger Price
[ Thu, Jan 23rd 2025 ]: MSN
How to Get Your Kids into Investing: A Family Project to Try
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of TENB at $4 .. 1, after crossing above the $42.514 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of UGI at $30 .. 9, after crossing above the $30.301 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of SD at $12.4, after crossing above the $12.372 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of PHG at $26 .. 2, after crossing above the $26.497 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of LVO at $1.25, after crossing above the $1.222 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of IVDN at $0 .. 32, after crossing above the $0.277 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of FMS at $24 .. 1, after crossing above the $23.655 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of BWB at $13 .. 5, after crossing above the $13.387 Trigger Price
[ Thu, Jan 23rd 2025 ]: WOPRAI
Short squeeze is starting in shares of BUSE at $2 .. 4, after crossing above the $22.952 Trigger Price
[ Thu, Jan 23rd 2025 ]: MSN
Dave Ramsey: If You Invested $10K in These Companies, You'd Be Nearly $16K Richer

Avidity Biosciences CFO sells $93,985 in stock

The article from MSN Money discusses a recent transaction by Avidity Biosciences' Chief Financial Officer (CFO), Michael F. MacLean, who sold shares of the company's stock. On June 12, 2023, MacLean sold 12,512 shares at an average price of $7.51 per share, totaling approximately $93,985. This sale was part of a series of insider transactions at Avidity Biosciences, where insiders have been both buying and selling shares over the past year. The article provides context on insider trading, noting that while such sales can sometimes signal a lack of confidence in the company's future, they can also be for personal financial reasons unrelated to the company's performance. Avidity Biosciences, a clinical-stage biopharmaceutical company, focuses on developing treatments for rare diseases, and its stock performance and insider trading activities are often closely watched by investors for insights into the company's health and prospects.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/topstocks/avidity-biosciences-cfo-sells-93-985-in-stock/ar-AA1xLaPh ]